Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Yakobson

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Current Oncology (Toronto, Ont.)|January 20, 2022
Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?Walid Shalata, Alexander Yakobson, Rachel Steckbeck, et al.
Cancers|October 23, 2021
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic ReviewWalid Shalata, Amjad Abu-Salman, Rachel Steckbeck, et al.
Cancers|August 29, 2024
Mental Health Challenges in Cancer Patients: A Cross-Sectional Analysis of Depression and AnxietyWalid Shalata, Itamar Gothelf, Tomer Bernstine, et al.
Frontiers in Immunology|March 18, 2026
Fulminant multi-organ myositis as a rare immune-related adverse event of nivolumab-relatlimab (Opdualag) therapy in metastatic melanoma: a case reportAdi Moyal, Elimelech Rosenberg, Mohamed Asale, et al.
Oncology|June 9, 2022
Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution ExperienceWalid Shalata, Alexander Yakobson, Sarah Weissmann, et al.
Life (Basel, Switzerland)|January 21, 2023
Dermatomyositis Associated with Lung Cancer: A Brief Review of the Current Literature and Retrospective Single Institution ExperienceWalid Shalata, Jeremy Zolnoorian, Amichay Meirovitz, et al.
Life (Basel, Switzerland)|August 26, 2023
Unexpected Adverse Events of Immune Checkpoint InhibitorsWalid Shalata, Alexander Yakobson, Aharon Y Cohen, et al.
Journal of Thoracic Disease|September 18, 2020
Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancerWaleed Kian, Laila C Roisman, Nadav Wallach, et al.
Anti-Cancer Drugs|July 7, 2021
Metastatic small cell lung cancer - an aggressive disease: a case report and literature reviewWalid Shalata, Ismaell Massalha, Keren Rouvinov, et al.
International Journal of Molecular Sciences|March 29, 2023
Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World ExperienceWalid Shalata, Jeremy Zolnoorian, Gabrielle Migliozzi, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Current Oncology (Toronto, Ont.)|January 20, 2022
Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?Walid Shalata, Alexander Yakobson, Rachel Steckbeck, et al.
Cancers|October 23, 2021
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic ReviewWalid Shalata, Amjad Abu-Salman, Rachel Steckbeck, et al.
Cancers|August 29, 2024
Mental Health Challenges in Cancer Patients: A Cross-Sectional Analysis of Depression and AnxietyWalid Shalata, Itamar Gothelf, Tomer Bernstine, et al.
Frontiers in Immunology|March 18, 2026
Fulminant multi-organ myositis as a rare immune-related adverse event of nivolumab-relatlimab (Opdualag) therapy in metastatic melanoma: a case reportAdi Moyal, Elimelech Rosenberg, Mohamed Asale, et al.
Oncology|June 9, 2022
Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution ExperienceWalid Shalata, Alexander Yakobson, Sarah Weissmann, et al.
Life (Basel, Switzerland)|January 21, 2023
Dermatomyositis Associated with Lung Cancer: A Brief Review of the Current Literature and Retrospective Single Institution ExperienceWalid Shalata, Jeremy Zolnoorian, Amichay Meirovitz, et al.
Life (Basel, Switzerland)|August 26, 2023
Unexpected Adverse Events of Immune Checkpoint InhibitorsWalid Shalata, Alexander Yakobson, Aharon Y Cohen, et al.
Journal of Thoracic Disease|September 18, 2020
Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancerWaleed Kian, Laila C Roisman, Nadav Wallach, et al.
Anti-Cancer Drugs|July 7, 2021
Metastatic small cell lung cancer - an aggressive disease: a case report and literature reviewWalid Shalata, Ismaell Massalha, Keren Rouvinov, et al.
International Journal of Molecular Sciences|March 29, 2023
Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World ExperienceWalid Shalata, Jeremy Zolnoorian, Gabrielle Migliozzi, et al.
Pageof 7